References


  1. BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals 2016 (2019 interim update). Available at:   https://www.bhiva.org/monitoring-guidelines
  2. Laboratory Testing for Initial Assessment and Monitoring of Patients with HIV Receiving Antiretroviral Therapy. US Guidelines for the Use of Antiretroviral Agents in Adults and    Adolescents with HIV. Available at:  https://aidsinfo.nih.gov/guidelines/html/1/adult-and-       adolescent-arv/3/tests-for-initial-assessment-and-follow-up
  3. European AIDS Clinical Society (EACS) HIV Guidelines Version 10.0. https://eacs.sanfordguide.com/
  4. Chronic kidney disease management in primary care 2020. Available at:  https://kidney.org.au/health-professionals/ckd-management-handbook
  5. Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads.  J Infect Dis. 2004; 189:1452-1465. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15073683.
  6. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. US Department of Health and Human Services. Available       at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/15/virologic-  failure
  7. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV:       recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at             http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 6 April 2021.
  1. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV     infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind,   randomised, non-inferiority, phase 3 trials. Lancet 2019; 393:143-155.
  1. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virological suppression in adults living with human immunodeficiency virus type-1: phase 3, randomised, noninferiority TANGO study. Clin Infect         Dis 2020; 7:1920-9.
  2. Van Wyk, Ajana F, Bisshop F et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study). Abstract 0441. Abstract Supplement HIV     Glasgow – Virtual, 5-8 October 2020. J Int AIDS Soc 2020; 23: e25616
  3. Figueroa MI, Sued OG, Gun AM, et al. DRV/R FDC plus 3TC for HIV-1 treatment-naive patients: Week 48 results of the ANDES study. CROI 2018, Abstract #489 http://www.croiconference.org/sessions/drvr3tc-fdc-hiv-1-treatment-na%C3%AFve-patients-week-48-results-andes-study
  4. Corado KC, Caplan MR, Daar ES. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy. Drug Des Devel Ther 2018; 12:3731-40.
  5. Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the       randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. The Lancet HIV 2019;           6:e576-e587.
  6. Rizzardini G, Overton ET, Orkin C, et al. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J        Acquir Immune Defic Syndr. 2020; 85:498-506.
  7. Swindells S, Lutz T, Van Zyl L, et al. Cabotegravir + rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS week 96 results. HIV Glasgow (Virtual) 2020, Abstract #P006. Supplement - J Int AIDS Soc 2020; 23:e25616.
  8. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised,        multicentre, open-label, phase 3b, non-inferiority study. Lancet 2021; 396(10267):1994-        2005.
  9. Margolis D, Schapiro J, Perno C, et al. A combination of viral and participant factors influence virological outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analysis across ATLAS, FLAIR, and ATLAS-2M phase III studies. HIV Glasgow (Virtual) 2020, Abstract #0442. Supplement - J Int AIDS Soc 2020; 23:e25616.
  10. Di Cristo V, Adorni F, Maserati R, et al. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation. HIV Res Clin Pract.        2020; 21:34-43.
  11. McMahon JH, Moore R, Eu B, et al. Clinic network collaboration and patient tracing to maximise retention in HIV care. PLoS ONE 2015; 10:e0127726.
  12. Bulsara SM, Wainberg ML, Newton-John TRO. Predictors of adult retention in HIV care: a systematic review. AIDS Behav. 2018; 22:752-764.
  13. University of Washington, US. National HIV Curriculum - Retention in HIV care. Available at: https://www.hiv.uw.edu/go/basic-primary-care/retention-care/core-concept/all